Skip to main content

Table 1 Baseline characteristics of the ESPOIR patients who received methotrexate or its equivalent as a first-line biologic agent for rheumatoid arthritis.

From: Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort

  SD-treated patients
(number = 370)
All ESPOIR patients
(number = 813)
Age, years 49.4 ± 11.4 (51.5) 48.1 ± 12.5 (50.1)
Female sex 271 (73.2%) 624 (76.7%)
Disease duration, weeks 15.2 ± 15.4 (57.7) 31.6 ± 37.1 (21.3)
Swollen joint count in 28 joints 7.9 ± 5.4 (7) 7.2 ± 5.4 (6)
Tender joint count in 28 joints 8.7 ± 6.9 (7) 8.4 ± 7 (6)
ESR, mm/1st hour 32.7 ± 25 (26) 29.4 ± 24.6 (22)
CRP, mg/L 24.8 ± 37.7 (11) 20.3 ± 32.4 (9)
DAS28(ESR)-4v 5.4 ± 1.2 (5.2) 5.1 ± 1.3 (5.1)
IgM RF positivity 204 (55.1%) 376 (45.8%)
ACPA positivity 185 (50%) 315 (38.8%)
Typical erosion on radiographs 66 (17.8%) 100 (13.6%)
vSHS score 6.02 ± 9.7 [54] 3.71 ± 5.71 [54]
ACR/EULAR 2010 criteria 316 (85.4%) 582 (79.1%)
HAQ score 1.03 ± 0.7 (1) 0.979 ± 0.684
First-line agent:   
- No DMARDs n.a. 207 (25.5%)
- DMARDs without structural effect n.a. 117 (14.4%)
- Methotrexate or leflunomide 370 (100%) 396 (48.7%)
- Other DMARDs with structural effect n.a. 56 (6.9%)
- Tumor necrosis factor blockers alone or in combination n.a. 37 (4.6%)
  1. Data are mean ± SD (median) or number (%); n.a.; not available. Baseline CRP level (normally < 10 mg/l), IgM and IgA RF (ELISA, Menarini, France; positive > 9 UI/ml) and anti-CCP2 antibodies (ACPA; ELISA, DiaSorin, France; positive > 50 U/ml) were detected in all patients with the same technique in a central lab (Paris-Bichat). ACPA, anti-citrullinated protein antibody; ACR/EULAR, American College of Rheumatology/European League Against Rheumatism; CRP, C-reactive protein; DAS28(ESR)-4v, Disease Activity Score in 28 joints-4 variables, using erythrocyte sedimentation rate; DMARD, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IgM, immunoglobulin M; RF, rheumatoid factor; SD, synthetic DMARD; vSHS, van der Heijde-modified Sharp score.